glp-1 in type 1 diabetes for weight loss Therapy and GLP-1 Medications: Is Ozempic the

Int J Mol Sci 25:1087

Kanoski S.E., Hayes M.R., Skibicka K.P

FDA adverse event data The FDA Adverse Event Reporting System (FAERS) database provides additional context

Semaglutide was associated with gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation) which were of mild to moderate severity, short duration, and resolved without treatment discontinuation ( Notably, a recent systematic review showed that compared to other semaglutide doses and GLP-1 RAs, 2.4 mg semaglutide had the greatest effect on weight reduction, controlling glucose level, and reducing BP

The study, titled Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials, analyzed data about side effects people experienced after taking semaglutide drugs, such as Ozempic

Some preliminary evidence suggests that eating patterns that avoid prolonged fasting followed by large meals may support more consistent incretin responses